We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Dolomite Bio Introduces the Nadia Product Family for Single Cell Research

Dolomite Bio Introduces the Nadia Product Family for Single Cell Research content piece image
Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute
Dolomite Bio is delighted to announce the launch of the game-changing Nadia single cell platform, a groundbreaking system set to escalate scRNA-Seq to new heights, offering the fast-growing single cell research sector an innovative solution for a wide range of potential applications.

The Nadia instrument is a touchscreen-controlled, droplet-based microfluidic platform for single cell research, combining superior microfluidics, automated temperature control and gentle cell/bead agitation to offer a single compact instrument that delivers highly precise and reliable results. One, two, four or eight samples can be run in parallel, generating up to 6,000 high quality, single cell libraries per sample in approximately 15 minutes. Configuration with the Nadia Innovate protocol development platform transforms the system into a scalable, open system for the creation of new procedures and applications. Users can alter parameters – such as droplet size and frequency, temperature, agitation and timings – and optimize protocols with the aid of real-time visualization, enabling straightforward development of new single cell protocols and applications.

Mike Hawes, CEO of Dolomite Bio, commented: “We are excited to be launching the Nadia product family at conferences across three continents. This novel system represents a huge leap forward for single cell research, and we look forward to showcasing its capabilities.”